Discover
SLXN
Silexion Therapeutics Ltd.
2.51
20 x 2.48
1 x 2.64
bid
ask
-
0.00
0.04%
08:24 AM
timesize
| Ytd | -86.93% | |
| 1y | -98.02% |
2.56
day range
2.63
2.31
52 week range
223.60
| Open | 2.57 | Prev Close | 2.51 | Low | 2.56 | High | 2.63 | Mkt Cap | 1.05M |
| Vol | 852.00 | Avg Vol | 640.88K | EPS | -39.55 | P/E | -0.06 | Forward P/E | -3.95 |
| Beta | -0.26 | Short Ratio | 0.23 | Inst. Own | 8.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 3.54 | 200-d Avg | 16.83 | 1yr Est | 9.00 |
| Income Statement | |||
| Operating Expenses | 2.75M | ||
| Research and Development Expense | 1.37M | ||
| Selling, General and Administrative Expense | 1.38M | ||
| Operating Income | -2.75M | ||
| Interest Expense | -16.00K | ||
| Net Income | -2.73M | ||
| Net Income Common Stock | -2.73M | ||
| Net Income Common Stock (USD) | -2.73M | ||
| Consolidated Income | -2.73M | ||
| Earnings per Basic Share | -8.50 | ||
| Earnings per Basic Share (USD) | -8.50 | ||
| Earnings per Diluted Share | -8.50 | ||
| Earning Before Interest & Taxes (EBIT) | -2.75M | ||
| Earning Before Interest & Taxes (USD) | -2.75M | ||
| Weighted Average Shares | 323.04K | ||
| Weighted Average Shares Diluted | 323.04K | ||
| Balance Sheet | |||
| Cash and Equivalents | 2.44M | ||
| Cash and Equivalents (USD) | 2.44M | ||
| Investments | 58.00K | ||
| Investments Non-Current | 58.00K | ||
| Current Assets | 4.07M | ||
| Property, Plant & Equipment Net | 403.00K | ||
| Total Assets | 4.60M | ||
| Debt Current | 1.74M | ||
| Total Debt | 1.99M | ||
| Current Liabilities | 4.06M | ||
| Debt Non-Current | 251.00K | ||
| Total Liabilities | 4.31M | ||
| Accumulated Retained Earnings (Deficit) | -57.90M | ||
| Shareholders Equity | 291.00K | ||
| Shareholders Equity (USD) | 291.00K | ||
| Assets Non-Current | 537.00K | ||
| Total Debt (USD) | 1.99M | ||
| Liabilities Non-Current | 251.00K | ||
| Trade and Non-Trade Payables | 1.76M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.00K | ||
| Net Cash Flow from Financing | 83.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -3.56M | ||
| Issuance (Purchase) of Equity Shares | 83.00K | ||
| Net Cash Flow from Operations | -3.65M | ||
| Effect of Exchange Rate Changes on Cash | -14.00K | ||
| Share Based Compensation | 345.00K | ||